Effect of Erlotinib Plus Bevacizumab vs Erlotinib Alone on Progression-Free Survival in Patients With Advanced EGFR-Mutant Non–Small Cell Lung Cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Effect of Erlotinib Plus Bevacizumab vs Erlotinib Alone on Progression-Free Survival in Patients With Advanced EGFR-Mutant Non–Small Cell Lung Cancer

Published:2019-10-01 Issue:10 Volume:5 Page:1448
ISSN:2374-2437
Container-title:JAMA Oncology
language:en
Short-container-title:JAMA Oncol

Author:

Stinchcombe Thomas E.¹,Jänne Pasi A.²,Wang Xiaofei³,Bertino Erin M.⁴,Weiss Jared⁵,Bazhenova Lyudmila⁶,Gu Lin³,Lau Christie²,Paweletz Cloud²,Jaslowski Anthony⁷,Gerstner Gregory J.⁸,Baggstrom Maria Q.⁹,Graziano Stephen¹⁰,Bearden James¹¹,Vokes Everett E.¹²

Affiliation:

1. Duke Cancer Institute, Durham, North Carolina

2. Dana Farber Cancer Institute, Boston, Massachusetts

3. Alliance Data and Statistical Center, Department of Biostatistics and Bioinformatics, Duke University, Durham, North Carolina

4. The Ohio State University Comprehensive Cancer Center, Columbus

5. University of North Carolina Lineberger Cancer Center at Chapel Hill

6. Moores Cancer Center, University of California, San Diego

7. Saint Vincent Hospital Cancer Center, Green Bay, Wisconsin

8. Illinois Cancer Care-Peoria, Peoria, Illinois

9. Division of Medical Oncology, Washington University School of Medicine in St Louis, Missouri

10. Division of Hematology and Oncology, State University of New York Upstate Medical University, Syracuse

11. Spartanburg Regional Health, Spartanburg, South Carolina

12. Biological Sciences Division, University of Chicago Medicine, Chicago, Illinois

Publisher

American Medical Association (AMA)

Subject

Oncology,Cancer Research

Link

https://jamanetwork.com/journals/jamaoncology/articlepdf/2747878/jamaoncology_stinchcombe_2019_oi_190047.pdf

Reference37 articles.

1. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database.;Govindan;J Clin Oncol,2006

2. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.;Paez;Science,2004

3. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.;Lynch;N Engl J Med,2004

4. Screening for epidermal growth factor receptor mutations in lung cancer.;Rosell;N Engl J Med,2009

5. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs.;Kris;JAMA,2014

Cited by 94 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Meta-analysis of Targeted Therapies in EGFR-mutated Non–Small Cell Lung Cancer;American Journal of Clinical Oncology;2024-09-11

2. EGFR-TKIs or EGFR-TKIs combination treatments for untreated advanced EGFR- mutated NSCLC: a network meta-analysis;2024-09-11

3. Gefitinib (an EGFR tyrosine kinase inhibitor) plus anlotinib (an multikinase inhibitor) for untreated, EGFR-mutated, advanced non-small cell lung cancer (FL-ALTER): a multicenter phase III trial;Signal Transduction and Targeted Therapy;2024-08-13

4. The incidence of drug-induced interstitial lung disease caused by epidermal growth factor receptor tyrosine kinase inhibitors or immune checkpoint inhibitors in patients with non-small cell lung cancer in presence and absence of vascular endothelial growth factor inhibitors: a systematic review;Frontiers in Oncology;2024-06-11

5. The role of angiogenesis inhibitors associated with tyrosine kinase inhibitors in the first-line treatment for EGFR-mutated advanced lung cancer;Critical Reviews in Oncology/Hematology;2024-04

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3